Zobrazeno 1 - 10
of 643
pro vyhledávání: '"Jennifer A Wargo"'
Autor:
James L Gulley, Deborah Collyar, Pedro J Romero, Christian M Capitini, Leisha A Emens, Avery D Posey, Patrick Hwu, Jennifer A Wargo, Ann W Silk, Ana Carrizosa Anderson, Tullia C Bruno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antig
Externí odkaz:
https://doaj.org/article/ba0feaa1364741509df21dfe108b7d2c
Autor:
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, Jennifer Ferguson, Loredana Spoerri, Nikolas K Haass, Olivia Sloss, Sophie McEntegart, Imanol Arozarena, Alex vonKriegsheim, Javier Rodriguez, Holly Brunton, Jivko Kmarashev, Mitchell P Levesque, Reinhard Dummer, Dennie T Frederick, Miles C Andrews, Zachary A Cooper, Keith T Flaherty, Jennifer A Wargo, Claudia Wellbrock
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 8, Pp 1011-1029 (2017)
Abstract Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a “MITF‐high” phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also conta
Externí odkaz:
https://doaj.org/article/7cabb6c3861544079d79157438ec0d09
Autor:
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, Subash Baniya, Zachary A Cooper, Adriano Piris, Leeza Hargreaves, Vivien Igras, Dennie T Frederick, Donald P Lawrence, Daniel A Haber, Keith T Flaherty, Jennifer A Wargo, Sridhar Ramaswamy, Cyril H Benes, David E Fisher
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140310 (2015)
A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events have resulted in high single-agent or single-pathway response rates in selected patients, but few patients achieve complete responses and a sizeable fraction o
Externí odkaz:
https://doaj.org/article/2c65cc61a9ae4bf8a9a2e40f9c38d289
Autor:
Samuel A Shelburne, Nadim J Ajami, Marcus C Chibucos, Hannah C Beird, Jeffrey Tarrand, Jessica Galloway-Peña, Nathan Albert, Roy F Chemaly, Shashank S Ghantoji, Lisa Marsh, Naveen Pemmaraju, Michael Andreeff, Elizabeth J Shpall, Jennifer A Wargo, Katayoun Rezvani, Amin Alousi, Vincent M Bruno, Phillip A Futreal, Joseph F Petrosino, Dimitrios P Kontoyiannis
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0139851 (2015)
Disease can be conceptualized as the result of interactions between infecting microbe and holobiont, the combination of a host and its microbial communities. It is likely that genomic variation in the host, infecting microbe, and commensal microbiota
Externí odkaz:
https://doaj.org/article/da893cf3d97644d38a253b03fb6e28fe
Autor:
Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101286 (2014)
While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We analyze
Externí odkaz:
https://doaj.org/article/8814805ec5d04e5395a5f296e5e3124d
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
Autor:
Chieko Michikawa, Vancheswaran Gopalakrishnan, Amani M. Harrandah, Tatiana V Karpinets, Rekha Rani Garg, Randy A. Chu, Yuk Pheel Park, Sasanka S. Chukkapallia, Nikhita Yadlapalli, Kelly C. Erikson-Carter, Frederico Omar Gleber-Netto, Elias Sayour, Ann Progulske-Fox, Edward K.L. Chan, Xiaogang Wu, Jianhua Zhang, Christian Jobin, Jennifer A. Wargo, Curtis R. Pickering, Jeffrey N. Myers, Natalie Silver
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 31, Iss , Pp 100813- (2022)
Recently, increased number of studies have demonstrated a relationship between the oral microbiome and development of head and neck cancer, however, there are few studies to investigate the role of oral bacteria in the context of the tumor microenvir
Externí odkaz:
https://doaj.org/article/974eabb64e8544b885cd3daac2802a36
Autor:
Joon Seok Park, Francesca S. Gazzaniga, Meng Wu, Amalia K. Luthens, Jacob Gillis, Wen Zheng, Martin W. LaFleur, Sarah B. Johnson, Golnaz Morad, Elizabeth M. Park, Yifan Zhou, Stephanie S. Watowich, Jennifer A. Wargo, Gordon J. Freeman, Dennis L. Kasper, Arlene H. Sharpe
Publikováno v:
Nature. 617:377-385
Autor:
Tina Cascone, Cheuk H. Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy, Hope Feldman, William N. William, Yuanxin Xi, Sreyashi Basu, Jing Jing Sun, Shalini S. Yadav, Frank R. Rojas Alvarez, Younghee Lee, Aditya K. Mishra, Lili Chen, Monika Pradhan, Haiping Guo, Ansam Sinjab, Nicolas Zhou, Marcelo V. Negrao, Xiuning Le, Carl M. Gay, Anne S. Tsao, Lauren Averett Byers, Mehmet Altan, Bonnie S. Glisson, Frank V. Fossella, Yasir Y. Elamin, George Blumenschein, Jianjun Zhang, Ferdinandos Skoulidis, Jia Wu, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Ravi Rajaram, Mara B. Antonoff, Junya Fujimoto, Luisa M. Solis, Edwin R. Parra, Cara Haymaker, Ignacio I. Wistuba, Stephen G. Swisher, Ara A. Vaporciyan, Heather Y. Lin, Jing Wang, Don L. Gibbons, J. Jack Lee, Nadim J. Ajami, Jennifer A. Wargo, James P. Allison, Padmanee Sharma, Humam Kadara, John V. Heymach, Boris Sepesi
Publikováno v:
Nature Medicine. 29:593-604
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant N
Autor:
Gabriele Romano, Francesca Paradiso, Peng Li, Pooja Shukla, Lindsay N. Barger, Olivia El Naggar, John P. Miller, Roger J. Liang, Timothy L. Helms, Alexander J. Lazar, Jennifer A. Wargo, Francesca Taraballi, James C. Costello, Lawrence N. Kwong
Publikováno v:
Cancer Immunology Research. 11:558-569
Patients with BRAF-mutant melanoma show significant responses to combined BRAF and MEK inhibition, but most relapse within 2 years. A major reservoir for drug resistance is minimal residual disease (MRD), comprised of drug-tolerant tumor cells laying
Autor:
Daniel K. Lester, Chase Burton, Alycia Gardner, Patrick Innamarato, Krithika Kodumudi, Qian Liu, Emma Adhikari, Qianqian Ming, Daniel B. Williamson, Dennie T. Frederick, Tatyana Sharova, Michael G. White, Joseph Markowitz, Biwei Cao, Jonathan Nguyen, Joseph Johnson, Matthew Beatty, Andrea Mockabee-Macias, Matthew Mercurio, Gregory Watson, Pei-Ling Chen, Susan McCarthy, Carlos MoranSegura, Jane Messina, Kerry L. Thomas, Lancia Darville, Victoria Izumi, John M. Koomen, Shari A. Pilon-Thomas, Brian Ruffell, Vincent C. Luca, Robert S. Haltiwanger, Xuefeng Wang, Jennifer A. Wargo, Genevieve M. Boland, Eric K. Lau
Publikováno v:
Nature Cancer. 4:222-239
Despite reports of striking outcomes, immunotherapy efficacy in melanoma is limited to subsets of patients 1, 2. Combining immunotherapies with other modalities has yielded limited improvements but also adverse events requiring cessation of treatment